These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 30051404)
41. Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. Chan SY; Rubin LJ Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263174 [TBL] [Abstract][Full Text] [Related]
42. Discovery of a murine model of clinical PAH: Mission impossible? Dai Z; Zhao YY Trends Cardiovasc Med; 2017 May; 27(4):229-236. PubMed ID: 28089339 [TBL] [Abstract][Full Text] [Related]
43. Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in Bmpr2(+/-) Mice with Schistosomiasis. Crosby A; Soon E; Jones FM; Southwood MR; Haghighat L; Toshner MR; Raine T; Horan I; Yang P; Moore S; Ferrer E; Wright P; Ormiston ML; White RJ; Haight DA; Dunne DW; Morrell NW Am J Respir Crit Care Med; 2015 Dec; 192(11):1355-65. PubMed ID: 26308618 [TBL] [Abstract][Full Text] [Related]
44. Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response. Mair KM; Johansen AK; Wright AF; Wallace E; MacLean MR Br J Pharmacol; 2014 Feb; 171(3):567-79. PubMed ID: 23802760 [TBL] [Abstract][Full Text] [Related]
45. Downregulation of type II bone morphogenetic protein receptor in hypoxic pulmonary hypertension. Takahashi H; Goto N; Kojima Y; Tsuda Y; Morio Y; Muramatsu M; Fukuchi Y Am J Physiol Lung Cell Mol Physiol; 2006 Mar; 290(3):L450-8. PubMed ID: 16361357 [TBL] [Abstract][Full Text] [Related]
46. Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Antigny F; Hautefort A; Meloche J; Belacel-Ouari M; Manoury B; Rucker-Martin C; Péchoux C; Potus F; Nadeau V; Tremblay E; Ruffenach G; Bourgeois A; Dorfmüller P; Breuils-Bonnet S; Fadel E; Ranchoux B; Jourdon P; Girerd B; Montani D; Provencher S; Bonnet S; Simonneau G; Humbert M; Perros F Circulation; 2016 Apr; 133(14):1371-85. PubMed ID: 26912814 [TBL] [Abstract][Full Text] [Related]
47. Pulmonary Arterial Hypertension and the Sex Hormone Paradox. Foderaro A; Ventetuolo CE Curr Hypertens Rep; 2016 Nov; 18(11):84. PubMed ID: 27832457 [TBL] [Abstract][Full Text] [Related]
48. Characteristics and risk factors of pulmonary arterial hypertension in patients with primary Sjögren's syndrome. Yan S; Li M; Wang H; Yang X; Zhao J; Wang Q; Liu Y; Lai J; Tian Z; Song H; Zhao Y; Zeng X Int J Rheum Dis; 2018 May; 21(5):1068-1075. PubMed ID: 29624870 [TBL] [Abstract][Full Text] [Related]
49. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension. Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747 [TBL] [Abstract][Full Text] [Related]
50. Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. Savale L; Guignabert C; Weatherald J; Humbert M Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653948 [TBL] [Abstract][Full Text] [Related]
55. α-Solanine reverses pulmonary vascular remodeling and vascular angiogenesis in experimental pulmonary artery hypertension. Nie X; Dai Y; Tan J; Chen Y; Qin G; Mao W; Zou J; Chang Y; Wang Q; Chen J J Hypertens; 2017 Dec; 35(12):2419-2435. PubMed ID: 28704260 [TBL] [Abstract][Full Text] [Related]
56. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190 [TBL] [Abstract][Full Text] [Related]
57. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats. Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924 [TBL] [Abstract][Full Text] [Related]
58. Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-β signaling. Chen M; Shen H; Zhu L; Yang H; Ye P; Liu P; Gu Y; Chen S J Cell Physiol; 2019 Aug; 234(10):17482-17493. PubMed ID: 30786011 [TBL] [Abstract][Full Text] [Related]
59. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation. Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075 [TBL] [Abstract][Full Text] [Related]
60. Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension. Morrell NW Adv Exp Med Biol; 2010; 661():251-64. PubMed ID: 20204735 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]